News | February 04, 2025
Gland Pharma reports Q3 FY25 revenue at Rs. 1,384 Cr
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
Morepen Laboratories approves hiving off of medical devices business
Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
Subscribe To Our Newsletter & Stay Updated
